Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

News
Video

Experts discuss best practices for educating patients with multiple myeloma on the adverse effects associated with talquetamab treatment.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a woman with dark curly hair wearing a floral shirt
Image of a woman with gray hair on a light blue background
Photo of a woman with a blue border around the image
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Graphic of a leukemia cell

FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

Chris Ryan
June 28th 2025
Article

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic of myeloma cells

Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden

Bridget Hoyt
June 25th 2025
Article

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Line illustration of blood cells on a blue background

Teclistamab Safe, Effective for Older Adults With Multiple Myeloma

Roman Fabbricatore
May 26th 2025
Article

CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.

Image of red blood cells

Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma

Chris Ryan
May 20th 2025
Article

CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.